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ABSTRACT 
Sylvatic rabies can be efficiently controlled by vaccination of foxes with a vaccinia-rabies 
recombinant virus. However, the risk of recombination between the engineered vaccine virus and 
other orthopoxviruses endemic in wildlife, such as cowpox virus, still needs to be investigated. In 
this study,f oxes inoculated orally and intradermally with cowpox virus were found to be not very 
susceptible to cowpox virus, which was isolated from only the oropharynx and tonsils, at low titre 
andfor onlyfive days after inoculation. Thus the risk of recombination between these viruses in 
foxes is very low. 
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Rabies remains a disease of major importance in Europe where the main vector is the red fox. 
Research has shown that control of sylvatic rabies is possible by vaccinating foxes with a vaccinia-
rabies recombinant vaccine which expresses the immunogenic glycoprotein of rabies virus1 
Previous experiments have demonstrated the efficacy and innocuity of this vaccine in target and 
non-target species2-5. The use of this vaccine is therefore preferable to the use of conventional 
attenuated strains of rabies virus which are pathogenic to some non-target species6-10. Several 
large-scale fox vaccination campaigns with this vaccine have led to almost complete elimination 
with this vaccine have led to almost complete elimination of rabies in Belgium11,12. However, before 
the recombinant vaccine can be routinely used in wildlife, it is important to know how its efficacy 
and safety might be affected by possible interaction with other orthopoxviruses, particularly 
cowpox virus, that are endemic in European wildlife. Cowpox virus is believed to circulate in 
populations of wild rodents from which transmission to other species, particularly domestic cats 
and man, may occur 14-18. The possibility of genetic recombination in the field between cowpox 
virus and the engineered vaccinia virus should not be ignored. For genetic vaccinia virus should not 
be ignored of the sites of virus replication after intradermal and oral inoculation. 
Materials and methods 
ANIMALS 
Twenty foxes aged between 4 and 5 months were captured in Belgium and kept in quarantine for 
one month before use in this study.  
VIRUSES 
Low-passage (sixth passage in Vero cells) cowpox virus strain L9720 and a recombinant vaccinia 
(Copenhagen strain) virus which expresses the rabies (ERA strain) glycoprotein (VVTGgRAB-26D3 
187XP)1 were used in this study. Both viruses were propagated on Vero cells with Dulbecco's 
Modified Eagle Medium (DMEM) supplemented by 5% fetal calf serum. 
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The susceptibility of foxes to cowpox virus was studied after intradermal or oral inoculation with 
different amounts of virus. Two foxes (foxes 1 and 2) were inoculated intradermally on the flank 
with 100 µl containing 0.25, 5, 102, 2 x 103, 4 x 104 and 2 x 105 plaque-forming units (p.f.u.) of cowpox 
virus and two (foxes 3 and 4) were inoculated intradermally with 7 x 102, 7 x 103, 7 x 104, 7 x 105 and 
7 x 106 p.f.u. of cowpox virus. Each fox was also inoculated with 100 µl of DMEM as control. A further 
two foxes (foxes 5 and 6) were inoculated with 100 µl containing 3 x 102, 3 x 103, 3 x 104. 3 x 105 and 3 
x 106 p.f.u. of vaccinia-rabies recombinant virus and DM EM. Two weeks after inoculation, foxes 
were killed by intracardiac injection of T61 (Hoechst Veterinar) after sedation with Hypnorm (0.1 ml 
kg-1 (Janssen Pharmaceutica). Ten foxes (foxes 7 to 16) were inoculated orally with 8 x 106 p.f.u. 
cowpox virus and two others (foxes 17 and 18) with 3 x 107 p.f.u. of the vaccinia-rabies recombinant 
virus (1 ml administered directly into the oral cavity). Two foxes (foxes 19 and 20) were inoculated 
orally with DMEM. Foxes were killed at various times after inoculation (Tables 1 and 2). Rectal 
temperatures were measured every two days. Blood samples and oropharyngeal and nasal swabs 
in 1 ml of medium were taken every two days and on the day of death. Buffy coats and plasma 
were separated by centrifugation at 1300g for 30 min and stored at -80°C for virus isolation and 
serology. 
SEROLOGY 
Antibody to Orthopoxvirus was determined by immunofiuorescence (IF) and haemagglutination 
inhib- ition (HAl)21. IF antibody titres were determined using cowpox virus-infected Vero cells in 96-
well plates and an anti-dog IgG FITC conjugate (Sigma). Titres were expressed as the reciprocal of 
the greatest dilution of serum which gave fluorescence. Rabies virus-neutralizing antibodies were 
determined by a fluorescence inhibition technique (RFFIT). Antibody titres were expressed in IU 
(international units) per ml as determined by comparison with a standard serum (titre = 4.4 1U ml –
1) 22. The arbitrarily defined level of 0.5 IU ml-1 in humans is considered indicative of successful 
rabies immunization. 
Published in : Vaccine (1995), vol. 13, n°2, pp. 215–219 
DOI: 10.1016/0264-410X(95)93139-Z 




VIRUS ISOLATION AND TITRATION 
After death, the following tissues were collected for virus isolation from each orally inoculated 
animal : tonsils, buccal mucosa, maxillary and parotid salivary glands, submaxillary, 
retropharyngeal, axillary, bronchial and mesenteric lymph nodes, thym us, spleen, liver, kidney, 
small and large intestine, Jung and brain. Tissues were washed in sterile phosphate-buffered saline 
containing antibiotics and stored at -80°C. Samples were weighed, ground, freeze-thawed three 
times and clarified by centrifugation for 15 min at 1300g. Swabs, buffy coats, plasma and clarified 
tissue samples were inoculated in Vero cells in 24-well plates. Three days after inoculation, cells 
were examined for cytopathic effect and negative samples were passaged once more. Virus 
isolated from tissues at first passage was titrated on Vero cells. Titres were expressed in p.f.u. ml-1 
for swabs and p.f.u. g-1 for tissues. 
HISTOLOGICAL EXAMINATION 
Skin samples from normal or depilated areas were fixed in 10% formol-saline or in 4% 
paraformaldehyde, and plastic-embedded (JB-4; Polysciences Ltd) before being processed and 
stained with haematoxylin and eosin. Imm unoperoxidase staining was undertaken using a rabbit 
hyperimmune anti-cowpox virus serum as previously described. 23 
Results 
CLINICAL SIGNS 
No obvious clinical signs were observed in any foxes apart from small depilated areas observed at 
the intradermal inoculation sites of ?105 p.f.u. cowpox or recombinant virus and a small induration 
in one fox (fox 2) at 102 p.f.u. from 4 to 8 days postinoculation (dpi). No pyrexia was detected in any 
fox. 
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No antibody to orthopoxviruses was detected in any fox by either IF or HAI assays at the beginning 
of the experiment. Foxes inoculated intradermally with cowpox virus developed detectable IF and 
HAI antibody by 6-15 dpi (Table I). A strong correlation was found between HAI and IF assays in all 
foxes. Of two foxes inoculated intradermally with vaccinia-rabies recombinant virus, one 
seroconverted at 7 dpi but no antibody was detected in the other. One fox inoculated orally with 
cowpox virus (fox 16) seroconverted at 9 dpi but no antibody was detected in any other fox 
inoculated orally with either virus (Table I). Five foxes had detectable antibody against rabies prior 
to the beginning of the experiment (Table I). These titres did not significantly vary during the 
experiment except in fox 5 which developed an increase in ra bies antibody titre 13 days after 
intradermal inoculation with recombinant virus (data not shown). 
VIRUS ISOLATION 
No viraemia was detected in any fox and no virus was isolated from swabs or tissues from foxes 
inoculated intradermally with either virus. From foxes inoculated orally, no virus was isolated from 
nasal swabs but cowpox virus was isolated at up to 103 p.f.u. ml -1 from oropharyngeal swabs until 5 
dpi and vaccinia-rabies recombinant virus was isolated from oropharyngeal swabs at 1 dpi (Table 
2). Cowpox virus was isolated from tonsils at up to 104 p.f.u. g –1 for 2-3 dpi and after passage until 5 
dpi. The recombinant virus was reisolated for only one day from tonsils (Table 2). No virus was 
detected in any other tissues tested. 
HISTOLOGICAL EXAMINATION 
Examination of the mild skin lesions which developed at some sites of intradermal inoculation 
revealed none of the changes usually associated with cowpox virus infection 2,3; no characteristic A-
type inclusions were seen and no Orthopoxvirus antigen was detected by immunoperoxidase 
staining (data not shown). 
Discussion 
Genetic recombination between orthopoxviruses and the production of recombinant viruses with 
novel biological properties after dual infection of cell and tissue cultures is a well known 
phenomenon 24-27. Similar recombination has also occurred in whole animals, for example among 
capripoxviruses 28 and leporipoxviruses 29. The purpose of the experiments described here was to 
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assess the risk of genetic recombination between cowpox and vaccinia-rabies recombinant viruses 
in foxes in the field. In order to evaluate the risk of such recombination, it was essential to 
determine first whether foxes were susceptible to cowpox virus. Intradermal titration of cowpox 
virus in the flanks of four foxes demonstrated that foxes are not very susceptible to infection by this 
route. Indeed, unlike cats, in which as little as 5 p.f.u. can cause primary lesions at the inoculation 
site, viraemia and secondary skin lesions2,3, only mild skin lesions, with no evidence of virus 
replication, were provoked when ≥ 2 x 105 p.f.u., or 102 p.f.u. in one case, of cowpox virus were 
inoculated into foxes. These lesions may be similar to those reported after abortive Avipoxvirus 
infection of mammals 30-32. No lesions at all were observed in foxes inoculated orally, although 
cowpox virus was isolated from sils and oropharyngeal swabs until 5 dpi, indicating that transient 
local infection probably did occur. However, no evidence of systemic infection was found in any 
fox. None of the foxes had detectable antibody against cowpox virus at the beginning of the 
experiment but all of those inoculated intradermally and one fox inoculated orally seroconverted 
at 6-15 dpi. Five foxes had detectable rabies antibody at the beginning of the experiment. The age 
and health of the foxes suggest that this antibody was unlikely to have been due to either rabies 
virus infection or maternally derived antibody. However, the foxes may have eaten baits containing 
the recombinant vaccine brought back to the earth by their mothers during a recent vaccination 
campaign. If some foxes had been previously exposed to the recombinant vaccine, then pre-
existing immunity might have reduced the susceptibility of some of these foxes to cowpox virus 
infection and might particularly have reduced the amounts of virus reisolated from foxes 8 and 9. 
However, only three of 14 foxes inoculated with cowpox had pre-existing rabies antibody so this 
argument does not affect the overall conclusion that foxes are relatively unsusceptible to cowpox. 
The prevalence of antibody to cowpox virus in wild foxes is low: none of 72 foxes from South 
Belgium had detectable Orthopoxvirus antibody (unpublished data). The low prevalence of 
Orthopoxvirus infection in foxes and the restricted replication of both cowpox and vaccinia-rabies 
recombinant viruses 19 suggests that the risk of recombination between these two viruses in foxes 
is very low. This work therefore adds support to arguments in favour of the use of the vaccinia-
rabies recombinant vaccine in large-scale vaccination campaigns to eliminate rabies in Europe. 
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Table 1. Serology for cowpox (IF) and rabies (RFFIT) in foxes inoculated orally or intradermally with cowpox or 
recombinant rabies-vaccinia virus 
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Légende de la table : acpx, cowpox virus; rec, rabies-vaccinia recombinant virus; i.d., intradermal - bReciprocal of last 
dilution which gave fluorescence - *Indicates the day on which foxes were killed 
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Table 2. Reisolation of cowbox and recombinant vaccinia viruses from oropharyngeal swabs and tonsils after 
oral inoculation 
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Légende de la figure. : indicates the day on which foxes were killed : - Indicates that no virus was isolated after two 
passages / +Indicates that virus was isolated but the titre was not determined (very low) (+) Indicates that virus was  
isolated after passage 
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